Trials / Unknown
UnknownNCT06171074
Study of CM310 in Subjects With Seasonal Allergic Rhinitis
A Multicenter, Single Arm Phase II Clinical Study Evaluating the Efficacy of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Seasonal Allergic Rhinitis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, single arm phase II clinical study mainly evaluating the efficacy of CM310 in patients with seasonal allergic rhinitis.
Detailed description
Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of the nasal mucosa that is mainly mediated by immunoglobulin E (IgE) in atopic individuals exposed to allergens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM310 | CM310 injection |
Timeline
- Start date
- 2024-03-30
- Primary completion
- 2025-03-30
- Completion
- 2025-03-30
- First posted
- 2023-12-14
- Last updated
- 2023-12-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06171074. Inclusion in this directory is not an endorsement.